NEWTOWN, Pa.—BioClinica, Inc., a specialty clinical trials services and technology provider, today announced that it has acquired Synowledge to expand its offering into the growing drug safety and regulatory business process outsourcing market. Headquartered in Miami, Synowledge specializes in pharmacovigilance, regulatory affairs and information technology services to support biopharmaceutical companies with recording, analyzing and reporting adverse drug events.
“This acquisition extends BioClinica’s solutions into an important new area for our customers,” said BioClinica President and CEO John Hubbard. “Synowledge is a highly regarded provider that biopharmaceutical corporations trust to manage the critical process of monitoring and reporting adverse drug events. It's capabilities complement our deep scientific expertise and technology-enabled services that support our customers in developing and bringing new drugs to market as safely and efficiently as possible.”
Since its founding in 2006, Synowledge has grown rapidly to serve many of the world’s leading pharmaceutical and biotechnology organizations. The company offers pharmacovigilance services across all therapeutic areas and stages of drug development, including case processing, aggregate reporting, medical literature review, call center support and signal detection. Synowledge employs a highly skilled global workforce of more than 500 people who provide customers with around-the-clock expertise and support remotely or onsite. The company also offers information technology services for drug safety applications.
Sankesh Abbhi, who founded Synowledge, said, “We are very pleased to become part of BioClinica. Our companies share a deep commitment to serving our customers and supporting their goals through highly specialized expertise and tailored solutions. Together, we offer customers a broader set of services and increased access to resources that support their overall drug development process.”
Effective immediately, Mr. Abbhi will serve as senior vice president and head of global safety and regulatory solutions. He will report to Mukhtar Ahmed, president of BioClinica’s eClinical Solutions Division.
“Synowledge is a proven industry leader in the adoption of pharmacovigilance and regulatory technologies,” said Mr. Ahmed. “With its depth of expertise in business process execution, data analysis and application-managed services, we will further extend our eClinical product and services portfolio so that we can provide our customers with a comprehensive offering that spans across the life-sciences landscape.”
BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica’s experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations—including all of the top 20—through a network of offices in the U.S., Europe and Asia.
Synowledge is a specialized pharmacovigilance, regulatory affairs and IT services provider that assists and enables small, medium and large life-sciences organizations to satisfy their global regulatory requirements. The Synowledge team consists of highly qualified and skilled experts who are committed to helping companies meet and exceed the challenging demands of the R&D lifecycle. The company’s comprehensive outsourcing solutions cover all therapeutic areas and combine the unique strengths and knowledge of industry leading experts. Synowledge was founded in 2006 and is headquartered in Miami, Florida. Synowledge has global offices in North America, Europe, India and Japan.